Drug Approval | February 20, 2025
Orchid Pharma's Alathur API facility successfully completes USFDA inspection
The Alathur facility specializes in the production of Cephalosporin antibiotics
The Alathur facility specializes in the production of Cephalosporin antibiotics
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
The company will showcase groundbreaking innovations from its Pharma and Nutrition divisions, highlighting key ingredients and formulations designed to support holistic well-being
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
The new facility, which has a capacity of 5,000 metric tonnes, will manufacture nutraceuticals and dietary-active ingredients for human consumption.
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
Subscribe To Our Newsletter & Stay Updated
